Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2025OncohematologyOpen Access

Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

МММ. A. МингалимовSechenov UniversityЕBЕ. А. BaryakhRussian Medical Academy of Continuous Professional EducationAMA. V. MisyurinSechenov University

Discussion

Loading...

Member takes

Implication

Assessment of acalabrutinib in R-CHOP therapy shows 100% response rate in newly diagnosed DLBCL patients, indicating effective treatment options.

Key Points

  • Acala-R-CHOP therapy achieved a 100% overall and complete metabolic response rate in newly diagnosed DLBCL patients.
  • The treatment demonstrated manageable toxicity, primarily myelosuppression, with a cohort of 15 patients aged 38 to 78.
  • The study focused on high-risk genetic variants like N1, MCD, and BN2, indicating optimized treatment is crucial for these subtypes.
  • Follow-up periods are essential for assessing long-term efficacy and safety outcomes in this patient population with specific genotypes.

Cite This Study

Мингалимов et al. (2025) studied this question.

synapsesocial.com/papers/68d45b3431b076d99fa5dc6fhttps://doi.org/10.17650/1818-8346-2025-20-3-22-26
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms2022 · 4,042 citations
  2. 2Diffuse large B-cell lymphoma: R-CHOP failure—what to do?2016 · 303 citations
  3. 3Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies2018 · 51 citations
  4. 4Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT2022 · 31 citations